Novo Nordisk Sees 15M Patient Gain as Medicare Covers Obesity Drugs
Novo Nordisk CEO Mike Doustdar targets 15 million new patients when Medicare begins covering its obesity treatments later this year. Negotiations on precise timing are underway as the company leverages GLP-1 drug price cuts—Wegovy pills listed at $149, an 89% discount—to boost prescriptions despite slow initial uptake.
1. Medicare Coverage Expansion
Novo Nordisk aims to enroll roughly 15 million Medicare beneficiaries once coverage for approved obesity treatments begins in mid-2026. CEO Mike Doustdar said finalizing the exact month and week of rollout with federal officials remains under negotiation.
2. GLP-1 Price Reductions
Under the drug-pricing agreement, Wegovy oral pills will carry a $149 list price—an 89% reduction from current levels—while injectable pens start at $199 with a $50 copay for patients, designed to offset lower realized prices.
3. Adoption Challenges and Competitive Pressure
Doustdar warned that rapid uptake is unlikely, pointing to slow adoption among commercially insured patients. Novo Nordisk faces competition from Eli Lilly’s Zepbound, compounded alternatives and ongoing legal disputes over unapproved Wegovy copycats.